307 related articles for article (PubMed ID: 37226190)
1. The artificial intelligence and machine learning in lung cancer immunotherapy.
Gao Q; Yang L; Lu M; Jin R; Ye H; Ma T
J Hematol Oncol; 2023 May; 16(1):55. PubMed ID: 37226190
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer.
Yin X; Liao H; Yun H; Lin N; Li S; Xiang Y; Ma X
Semin Cancer Biol; 2022 Nov; 86(Pt 2):146-159. PubMed ID: 35963564
[TBL] [Abstract][Full Text] [Related]
3. The EU-funded I
Prelaj A; Ganzinelli M; Trovo' F; Roisman LC; Pedrocchi ALG; Kosta S; Restelli M; Ambrosini E; Broggini M; Pravettoni G; Monzani D; Nuara A; Amat R; Spathas N; Willis M; Pearson A; Dolezal J; Mazzeo L; Sangaletti S; Correa AM; Aguaron A; Watermann I; Popa C; Raimondi G; Triulzi T; Steurer S; Lo Russo G; Linardou H; Peled N; Felip E; Reck M; Garassino MC
Clin Lung Cancer; 2023 Jun; 24(4):381-387. PubMed ID: 36959048
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
6. Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.
Cheng G; Zhang F; Xing Y; Hu X; Zhang H; Chen S; Li M; Peng C; Ding G; Zhang D; Chen P; Xia Q; Wu M
Front Immunol; 2022; 13():893198. PubMed ID: 35844508
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients.
Mei T; Wang T; Zhou Q
Clin Exp Med; 2024 Mar; 24(1):60. PubMed ID: 38554212
[TBL] [Abstract][Full Text] [Related]
8. When artificial intelligence meets PD-1/PD-L1 inhibitors: Population screening, response prediction and efficacy evaluation.
Jin W; Luo Q
Comput Biol Med; 2022 Jun; 145():105499. PubMed ID: 35439641
[TBL] [Abstract][Full Text] [Related]
9. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
[TBL] [Abstract][Full Text] [Related]
10. A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Non-Small Cell Lung Cancer.
Wu J; Lin D
Adv Anat Pathol; 2021 Nov; 28(6):439-445. PubMed ID: 34623343
[TBL] [Abstract][Full Text] [Related]
11. Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images.
Vahadane A; Sharma S; Mandal D; Dabbeeru M; Jakthong J; Garcia-Guzman M; Majumdar S; Lee CW
Comput Biol Med; 2023 Jan; 152():106337. PubMed ID: 36502695
[TBL] [Abstract][Full Text] [Related]
12. Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC.
Wang C; Ma J; Shao J; Zhang S; Li J; Yan J; Zhao Z; Bai C; Yu Y; Li W
Front Immunol; 2022; 13():828560. PubMed ID: 35464416
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
Dong A; Zhao Y; Li Z; Hu H
J Gene Med; 2021 Feb; 23(2):e3294. PubMed ID: 33171529
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
15. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
Baxi V; Lee G; Duan C; Pandya D; Cohen DN; Edwards R; Chang H; Li J; Elliott H; Pokkalla H; Glass B; Agrawal N; Lahiri A; Wang D; Khosla A; Wapinski I; Beck A; Montalto M
Mod Pathol; 2022 Nov; 35(11):1529-1539. PubMed ID: 35840720
[TBL] [Abstract][Full Text] [Related]
16. Transformation of a cold to hot tumor and a durable response to immunotherapy in a patient with non-small cell lung cancer after chemoradiotherapy: a case report.
Miao Q; Zhang L; Zheng X; Jiang K; Wu B; Lin G
Ann Palliat Med; 2021 Apr; 10(4):4982-4986. PubMed ID: 33966433
[TBL] [Abstract][Full Text] [Related]
17. Advances in artificial intelligence to predict cancer immunotherapy efficacy.
Xie J; Luo X; Deng X; Tang Y; Tian W; Cheng H; Zhang J; Zou Y; Guo Z; Xie X
Front Immunol; 2022; 13():1076883. PubMed ID: 36685496
[TBL] [Abstract][Full Text] [Related]
18. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
[TBL] [Abstract][Full Text] [Related]
19. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
20. [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].
;
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):743-752. PubMed ID: 34802204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
